P2RX7 and myeloid sarcoma: A limitation of targeting P2RX7 is that it may also be expressed by astrocytes and oligodendrocytes (albeit at low levels) (Zhao et al., 2021); however, immunostaining of brain tissue with MS active lesions demonstrated that P2RX7 antibodies labeled MHC class II + cells with a microglia-like morphology (Beaino et al., 2017).